The performance of abbreviated comprehensive geriatric assessment in elderly patients with diffuse large B cell lymphoma
- PMID: 39775268
- DOI: 10.1007/s00520-024-09142-6
The performance of abbreviated comprehensive geriatric assessment in elderly patients with diffuse large B cell lymphoma
Abstract
Purpose: Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive forms of non-Hodgkin's lymphoma. This study aimed to evaluate the performance of the abbreviated Comprehensive Geriatric Assessment (aCGA) in assessing frailty and predicting clinical outcomes in elderly patients with DLBCL.
Methods: A total of 91 patients aged ≥ 65 years with newly diagnosed DLBCL and who received immunochemotherapy at a single medical center in Taiwan between August 2019 and December 2022 were prospectively enrolled. Frailty was assessed in all participating patients within seven days of the first cycle of immunochemotherapy. The primary objective was to compare aCGA's accuracy in assessing frailty with that of the full CGA. Secondary objectives included assessing correlations between frailty and severe adverse events (sAEs), early mortality, and overall survival (OS).
Results: In the cohort, 50 (55%) and 38 (42%) patients were categorized as frail based on CGA and aCGA, respectively. A high number of aCGA domains impairment were positively associated with a high number of CGA domains impairment. The receiver operating characteristic for aCGA for detecting frailty was 0.846 (95% confidence interval [CI], 0.756-0.926). A cut-off point of ≥ 2 aCGA domain impairments indicated frailty, with a sensitivity of 70.0% and specificity of 92.7%. Based on aCGA, the early mortality rate was 7.5% and 26.3% (p = 0.019) for fit and frail patients, respectively. The 1-year and 2-year OS rates were 77.7% and 67.4% for fit patients, and 57.1% and 45.4% for frail patients, respectively. The adjusted hazard ratio for OS was 2.42 (95% CI, 1.06-5.49, p = 0.035) for frail patients compared to fit patients.
Conclusions: This finding suggested that aCGA could be used as an efficient alternative to the full CGA, potentially improving the clinical management and treatment decision-making for elderly patients with DLBCL.
Keywords: Frailty; Outcome; Prognosis; Screening tool; Vulnerability.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.Br J Haematol. 2019 Oct;187(1):73-81. doi: 10.1111/bjh.16049. Epub 2019 Jun 17. Br J Haematol. 2019. PMID: 31206608
-
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.Ann Hematol. 2023 Jun;102(6):1485-1500. doi: 10.1007/s00277-023-05233-2. Epub 2023 Apr 28. Ann Hematol. 2023. PMID: 37115298
-
Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy.Eur J Haematol. 2020 Oct;105(4):399-407. doi: 10.1111/ejh.13457. Epub 2020 Jul 2. Eur J Haematol. 2020. PMID: 32472712
-
Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches.Curr Oncol Rep. 2020 Aug 22;22(11):114. doi: 10.1007/s11912-020-00976-x. Curr Oncol Rep. 2020. PMID: 32827063 Review.
-
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.Curr Hematol Malig Rep. 2019 Aug;14(4):228-238. doi: 10.1007/s11899-019-00519-7. Curr Hematol Malig Rep. 2019. PMID: 31228094 Review.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- National Cancer Institute. "Surveillance Epidemiology and End Results (SEER) Program. Population Estimates Used in NCI’s SEER* Stat Software." https://seer.cancer.gov/statfacts/html/nhl.html Accessed November 11 2023
-
- Campo E, Harris NL, Jaffe ES, et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, editor. Lyon, France: International agency for research on cancer
-
- Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC (2021) Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv 5(9):2426–2437. https://doi.org/10.1182/bloodadvances.2021004665 - DOI - PubMed - PMC
-
- Goede V, Neuendorff NR, Schulz RJ, Hormigo AI, Martinez-Peromingo FJ, Cordoba R (2021) Frailty assessment in the care of older people with haematological malignancies. Lancet Healthy Longev 2(11):e736–e745. https://doi.org/10.1016/S2666-7568(21)00184-7 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials